相关临床试验
42
28 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
28
66.7%
已完成
1
2.4%
招募中
13
30.9%
暂无批准数据
- Faron Pharmaceuticals has appointed Jurriaan Dekkers as Chief Financial Officer, bringing over 20 years of biopharma experience including roles at AstraZeneca Netherlands and ProQR Therapeutics. - The appointment comes as Faron's lead immunotherapy asset bexmarilimab prepares to enter registrational studies, with CEO Juho Jalkanen highlighting Dekkers' fundraising and strategic growth expertise. - Current CFO Yrjö Wichmann will retire after playing a key role in the company's strategic transition and growth, remaining through Q1 2026 for continuity.
- Solve Therapeutics raised $120 million in an oversubscribed financing round led by Yosemite to accelerate development of its clinical-stage ADC pipeline featuring proprietary CloakLink™ linker technology. - The company's lead programs SLV-154 and SLV-324 are currently in Phase 1 clinical trials for solid tumors, with funding supporting completion of Phase 1b studies and operational expansion. - Solve's CloakLink™ platform addresses traditional ADC limitations by increasing stability and decreasing hydrophobicity, potentially enabling improved therapeutic indices and reduced toxicity. - The financing brings Solve's total capital raised to $321 million, following a $75 million round completed in December 2024.
- AstraZeneca has appointed Dr. Anas Younes as Chief Medical Officer while maintaining his role as Global Head of Hematology R&D and Chairman of Acerta's Board. - Dr. Younes brings over 25 years of lymphoma research experience and previously led clinical trials that resulted in FDA approval of the first targeted therapy and immune checkpoint inhibitor for lymphoma. - The appointment positions Dr. Younes to oversee AstraZeneca's entire medical strategy beyond hematology, extending his influence to the company's broader oncology and rare disease programs. - Under his leadership since 2018, AstraZeneca has expanded its hematology portfolio with acalabrutinib (Calquence®) as a cornerstone success and investments in next-generation platforms including antibody-drug conjugates and bispecific antibodies.
